Development and Validation of an Antibody for Detection of Lysine Homocysteinylation in Cobalamin Disorders

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH OLAO

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026Q00506

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

Q301

Additional Details
Set Aside

SBA

Place of Performance

Maryland, UNITED STATES

SourceSAM
Documents1
The National Institutes of Health (NIH), Office of Logistics and Acquisition Operations (OLAO), under the Department of Health and Human Services, has issued a presolicitation notice for the development and validation of a novel antibody specific to lysine homocysteinylation, a post-translational modification (PTM) implicated in cobalamin (vitamin B12) disorders. This procurement directly supports the U.S. Government’s mission to advance biomedical research on rare genetic diseases, improve public health outcomes, and foster the development of precision medicine. The primary objective of this initiative is to generate a PTM-specific antibody targeting N-homocysteine-lysine (N-homocysteinylation), for which no commercial antibodies currently exist. The successful contractor will be responsible for synthesizing and purifying peptide antigens containing N-homocysteinylated lysine residues, as well as matched control peptides with unmodified lysines. These peptides will be conjugated to carrier proteins (such as KLH) to facilitate immunization. The scope of work includes immunizing an appropriate host species—specifically rabbits for polyclonal antibody production—followed by the collection of polyclonal sera at multiple time points post-immunization. The generated sera will be tested on laboratory samples of N-homocysteinylated proteins derived from mouse models of MMACHC deficiency, a model relevant to cobalamin disorders. Additionally, ELISA screening will be performed to assess antibody specificity against both modified and unmodified peptides. Upon completion of the immunization schedule, a terminal bleed will be conducted, and the working antibody will be purified from the serum. The validated antibody will then be used to characterize proteins affected by this aberrant post-translational modification, with the long-term goal of elucidating disease mechanisms and informing the development of targeted therapies. This procurement is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), with a Product Service Code of Q301. The opportunity is set aside for SBA-eligible entities, and the place of performance is Maryland, United States. The contracting entity for this requirement is the National Institutes of Health OLAO. Interested parties may direct inquiries to the primary contact, John Burton, at [email protected]. The notice was originally posted on March 6, 2026, with a response deadline of June 13, 2026. Further details and any associated attachments can be accessed via the SAM.gov opportunity ID e00aeef0ae12495f9f15f62b4aff9f63. Contractors with expertise in antibody development, peptide synthesis, and immunological assay validation—particularly those with experience in rare disease research and post-translational modification detection—are encouraged to review the full presolicitation and consider aligning their capabilities with the outlined requirements.